Anti-cancer compound. Interferes with multiple cell signaling pathways, including cell cycle (cyclin D1 and cyclin E), apoptosis (activation of caspases and down-regulation of anti-apoptotic gene products), proliferation (HER-2, EGFR and AP-1), survival (PI3K/AKT pathway), invasion (MMP-9 and adhesion molecules), angiogenesis (VEGF), metastasis (CXCR-4) and inflammation (NF-kappaB, TNF, IL-6, IL-1, COX-2 and 5-LOX). Anti-angiogenic. Anti-metastatic. Anti-invasive. Chemopreventive. Hedgehog signaling (Hh) modulator. Downregulates Shh and Gli1.
Antioxidant. Anti-inflammatory. Potent inhibitor of NF-kappaB, cyclooxygenase-2 (COX-2), lipooxygenase (LOX), and inducible nitric oxide synthase (iNOS; NOSII). Downregulates the expression of various proinflammatory cytokines including TNF, IL-1, IL-2, IL-6, IL-8, IL-12 and chemokines.
Potent immunomodulator. Modulates several key transcription factors. Down-regulate transcription factors NF-kappaB, AP-1 and Egr-1. Down-regulates the expression of COX-2, LOX, NOS, MMP-9, uPA, TNF, chemokines, cell surface adhesion molecules and cyclin D1. Down-regulate growth factor receptors (such as EGFR and HER2) and inhibits the activity of c-Jun N-terminal kinase, protein tyrosine kinases and protein serine/threonine kinases.
Neuroprotective. Anti-amyloid activity.
Cardioprotective. p300/CBP-HAT inhibitor. Regulates lipid metabolism and downregulates obesity. Activates peroxisome proliferator-activated receptor-gamma (PPARgamma) and Nrf2 cell-signaling pathways. Antiviral, antibacterial, antifungal. Epigenetic agent. Interacts with histone deacetylases (HDACs), histone acetyltransferases (HATs), DNA methyltransferase I and microRNAs.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
Purity: >98% (HPLC)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
Anticancer potential of curcumin: preclinical and clinical studies: B.B. Aggarwal, et al.; Anticancer Res. 23, 363 (2003) (Review)
Curcumin: the story so far: R.A. Sharma, et al.; Eur. J. Cancer 41, 1955 (2005) (Review)
Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases: S. Bengmark; JPEN J. Parenter. Enteral. Nutr. 30, 45 (2006) (Review)
Multiple biological activities of curcumin: a short review: R.K. Maheshwari, et al.; Life Sci. 78, 2081 (2006) (Review)
"Spicing up" of the immune system by curcumin: G.C. Jagetia & B.B. Aggarwal; J. Clin. Immunol. 27, 19 (2007) (Review)
Curcumin: the Indian solid gold: B.B. Aggarwal, et al.; Adv. Exp. Med. Biol. 595, 1 (2007) (Review)
Antioxidant and anti-inflammatory properties of curcumin: V.P. Menon & A.R. Sudheer; Adv. Exp. Med. Biol. 595, 105 (2007) (Review)
Modulation of transcription factors by curcumin: S. Shishodia, et al.; Adv. Exp. Med. Biol. 595, 127 (2007) (Review)
Antitumor, anti-invasion, and antimetastatic effects of curcumin: G. Kuttan, et al.; Adv. Exp. Med. Biol. 595, 173 (2007) (Review)
Curcumin as an inhibitor of angiogenesis: S.S. Bhandarkar & J.L. Arbiser; Adv. Exp. Med. Biol. 595, 185 (2007) (Review)
Neuroprotective effects of curcumin: G.M. Cole, et al.; Adv. Exp. Med. Biol. 595, 197 (2007) (Review)
Immunomodulation by curcumin: S.C. Gautam, et al.; Adv. Exp. Med. Biol. 595, 321 (2007) (Review)
Curcumin and cancer: an "old-age" disease with an "age-old" solution: P. Anand, et al.; Cancer Lett. 267, 133 (2008) (Review)
Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases: B.B. Aggarwal & K.B. Harikumar; Int. J. Biochem. Cell Biol. 41, 40 (2009) (Review)
The protective role of curcumin in cardiovascular diseases: W. Wongcharoen & A. Phrommintikul; Int. J. Cardiol. 133, 145 (2009) (Review)
REVIEW: Curcumin and Alzheimer's disease: T. Hamaguchi, et al.; CNS Neurosci. Ther. 16, 285 (2010) (Review)
Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals: B.B. Aggarwal; Annu. Rev. Nutr. 30, 173 (2010) (Review)
Development of curcumin as an epigenetic agent: S. Fu & R. Kurzrock; Cancer 116, 4670 (2010) (Review)
The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer: F.H. Sarkar, et al.; Cancer Metastasis Rev. 29, 383 (2010) (Review)
Curcumin and obesity: evidence and mechanisms: L. Alappat & A.B. Awad; Nutr. Rev. 68, 729 (2010) (Review)
Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment: P. Basnet & N. Skalko-Basnet; Molecules 16, 4567 (2011) (Review)
Curcumin: a potential neuroprotective agent in Parkinson's disease: R.B. Mythri & M.M. Bharath; Curr. Pharm. Des. 18, 91 (2012) (Review)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|